Hafiz Ahmed
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$7.8MFederal grants as PI12 awards
1Patents grantedLatest Jan 27, 2026
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
12 awards · $7.8M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 27, 2024 | NIH | SBIR Phase II Targeting galectin-3 to overcome insulin resistance in type 2 diabetes | $1.9M | GLYCOMANTRA INC |
| Sep 1, 2023 | NIH | SBIR Phase II Targeting galectin-3 to overcome insulin resistance in type 2 diabetes | $1.8M | GLYCOMANTRA INC |
| Aug 30, 2023 | NIH | SBIR Phase II Targeting galectin-3 to overcome insulin resistance in type 2 diabetes | $1.8M | GLYCOMANTRA INC |
| Jul 19, 2023 | NIH | SBIR Phase I Targeting galectin-3 to intervene COVID-19 | $297K | GLYCOMANTRA INC |
| Aug 17, 2022 | NIH | SBIR Phase I Targeting galectin-3 to intervene COVID-19 | $300K | GLYCOMANTRA INC |
| May 22, 2020 | NIH | SBIR Phase I Targeting galectin-3 to overcome insulin resistance in type 2 diabetes | $300K | GLYCOMANTRA INC |
| Sep 18, 2018 | NIH | SBIR Phase I Targeting galectin-3 for treatment of NASH mediated fibrosis | $298K | GLYCOMANTRA INC |
| Sep 17, 2018 | NIH | SBIR Phase I Targeting galectin-3 to overcome drug resistance in metastatic prostate cancer therapy | $300K | GLYCOMANTRA INC |
| Sep 17, 2018 | NIH | SBIR Phase I Targeting galectin-3 for treatment of NASH mediated fibrosis | $298K | GLYCOMANTRA INC |
| Jul 15, 2016 | NIH | SBIR Phase I Targeting galectin-3 for prostate cancer therapy | $40K | GLYCOMANTRA INC |
| Jul 1, 2016 | NIH | SBIR Phase I Targeting galectin-3 for prostate cancer therapy | $265K | GLYCOMANTRA INC |
| Nov 23, 2015 | NIH | SBIR Phase I Targeting galectin-3 for prostate cancer therapy | $225K | GLYCOMANTRA INC |
2 patents as inventor
- US 12533394GLYCOMANTRA INCJan 27, 2026
- US GLYCOMANTRA INC—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#119
Awards as PI#86
Patents#155
Companies
- GLYCOMANTRA INCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.